ENA21 Poster 115

3D Ex Vivo Patient Tissue Platform for Oncology Drug Evaluation

Poster previously titled: “Novel Near Vivo Drug Response Platform for Oncology using 3D Ex Vivo Patient-Derived Microtumors”

Nataliia Beztsinna, Fanny Grillet^#, Niels Meesters, Donny van der Meer^#, Lidia Daszkiewicz, Kuan Yan, Emma Spanjaard, Willemijn Vader^# and Leo Price
^#VitroScan B.V. Leiden, The Netherlands

Despite advances in 3D tumor modeling, the endogenous cells of the tumor microenvironment (TME), such as immune cells, fibroblasts, and stromal components are absent. These TME components express important drug targets and they have been shown to play a critical role in drug response.

This poster details the establishment of a novel 3D Ex Vivo Patient Tissue Platform that combines a short-term 3D ex vivo tumor culture system using fresh patient tumors with the native TME intact with phenotypic high content image (HCI)-based analysis. This study entailed a detailed quantification of tumor sensitivity to targeted therapies, standard of care, and novel immunotherapies and drug combinations, tested on different cancer types.

Download this Poster to Discover:

• How the 3D HCI-based assay on ex vivo patient tumor material preserves the native TME and architecture
  
  
• That ex vivo testing using fresh patient tumor samples maintains intact endogenous immune cells to enable assessment of immune cell proliferation
  
  
• How the platform enables evaluation of varying responses to oncology and immuno-oncology drugs in high throughput

Download the Poster Now!